News on diagnostics for respiratory pathogens, including influenza, coronavirus, and more.
Stakeholders discussed last year's decision by Palmetto to deny coverage for large respiratory panels and discussed the way forward for test developers and labs.
Flu test sales were the second-highest for a quarter in the firm's history but were still $17.4 million lower than the year-ago quarter due to a much less intense flu season.
The company envisions creating a "vocometer … to provide disease screening and management solutions based on acoustic analysis of seconds of voice."
The funding will be used to run a study of breath-based biomarkers and measures of small airway function to enable the definitive diagnosis of asthma.
The new regulatory approvals add to previous approvals in Singapore, expanding the firm's reach in the Association of Southeast Asian Nations region.
